Fundz

Picard Medical

Tucson, Arizona, United States · Biotechnology, Health Care, Manufacturing

Picard Medical, Inc. is a medical technology company that specializes in developing innovative and effective medical devices for critical care and recovery environments. Their primary business activities involve designing and manufacturing advanced therapeutic tools aimed at improving patient outcomes, particularly in cardiovascular care. The company's flagship products include specialized monitor

Key facts

Headquarters
Tucson, Arizona, United States
Employees
Unknown
Industries
Biotechnology, Health Care, Manufacturing
Status
Public (PMI)
Website
picardmedical.com

Recent activity at Picard Medical

  • : SEC 8-K (5.02): On October 28, 2026, Picard Medical, Inc. appointed Dr. Richard Fang as the permanent Chief Executive Officer, effective immediately. Dr. Fang has been serving as the Interim CEO since June 2026 and brings over 20 years of experience in the medical device industry. His annual salary has been set at $0.4 million without any new or amended compensation arrangement resulting from this appointment. Additionally, the Company has existing loan agreements with entities affiliated with Dr. Fang, including a $0.7 million loan due in February 2027 at 6% interest, and a $0.5 million loan at 0% interest, which is due based on the condition of external funding. The strategic implications of Dr. Fang's leadership could potentially enhance the Company's growth trajectory given his extensive background in medical technology and previous success in leading companies in the field.
  • : SEC 8-K (1.01): On October 20, 2026, Picard Medical, Inc. entered into a Warrant Amendment and Exchange Agreement with its Warrant Holder and their designee. The agreement entails the surrender of common stock purchase warrants originally issued during a private placement in December 2025, in exchange for 200,000 shares of the Company's common stock. The warrants, previously exercisable for over 8 million shares, will be canceled upon exchange. The transaction is exempt from registration under Section 3(a)(9) of the Securities Act. The effective issuance of the Exchange Shares took place on October 22, 2026, upon meeting certain conditions, and there is no cash consideration involved in the exchange.
  • : SEC 8-K (2.03): On September 30, 2026, Picard Medical, Inc. issued three separate unsecured convertible notes with an aggregate principal amount of $1.0 million to accredited investors. Each note has an interest rate of 3.0% per annum and will mature on September 30, 2027. The Notes are designed to convert under specific conditions, and any default could trigger the entire outstanding balance to be declared due. This funding effort could significantly impact the company's cash flow and financial flexibility over the next year.
  • : SEC 8-K (7.01): On August 19, 2026, Picard Medical, Inc. released an investor presentation aimed at enhancing investor relations and communication. The presentation is intended for various business purposes related to investor awareness and company performance. This disclosure reflects the company's efforts to engage with shareholders and market participants while providing updated information about its strategies and operations. This initiative indicates the company's proactive stance in maintaining transparency and fostering investor confidence.
  • : SEC 8-K (8.01): On July 27, 2026, Picard Medical, Inc. announced via a press release that the NYSE American has accepted its Compliance Plan, indicating the company's adherence to stock exchange regulations. This acceptance is critical for the company's continued listing on the NYSE American. The detailed Compliance Plan is attached as Exhibit 99.1, reflecting the company's commitment to meet regulatory requirements. This event underscores the company's ongoing efforts to maintain its market position and operational compliance.
  • : SEC 8-K (8.01): On July 21, 2026, Picard Medical, Inc. announced the approval of a Reverse Stock Split through a press release. This Reverse Stock Split will become effective at the Effective Time, with the conversion of shares taking place on August 3, 2026, when the Company's Common Stock will trade on the NYSE American on a split-adjusted basis under the existing trading symbol 'PMI'. The stock will undergo a 1-for-50 split, reducing the total number of issued and outstanding shares while ensuring no fractional shares are created. A new CUSIP number 71953R 207 has been assigned for the split-adjusted stock.
  • : SEC 8-K (8.01):
  • : SEC 8-K (8.01): On July 2, 2026, Picard Medical, Inc. announced through a press release the availability of a pre-recorded presentation ahead of its 2026 Annual Meeting of Stockholders scheduled for July 17, 2026. The press release and the presentation are designed to provide information and updates relevant for stockholders ahead of the important meeting. This proactive communication aims to engage shareholders and ensure transparency about upcoming company developments. The public release also suggests significant strategic implications as it prepares stakeholders for future initiatives discussed during the meeting.
  • : SEC 8-K (5.02):
  • : SEC 8-K (5.02):

Picard Medical in the news

Companies similar to Picard Medical

  • Scarlet · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
  • ENvue Medical, Inc. · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
  • Capitan Orthopedics · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
  • Flyte Aviation, Inc. · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
  • Integris Medtech · Biotechnology, Health Care, Manufacturing, Medical, Medical Device

About Picard Medical: questions and answers

What does Picard Medical do?

Picard Medical, Inc. is a medical technology company that specializes in developing innovative and effective medical devices for critical care and recovery environments. Their primary business activities involve designing and manufacturing advanced therapeutic tools aimed at improving patient outcomes, particularly in cardiovascular care. The company's flagship products include specialized monitor

Where is Picard Medical headquartered?

Picard Medical is headquartered in Tucson, Arizona, United States.

What is the latest news on Picard Medical?

On Nov 03, 2026, SEC 8-K (5.02): On October 28, 2026, Picard Medical, Inc. appointed Dr. Richard Fang as the permanent Chief Executive Officer, effective immediately. Dr. Fang has been serving as the Interim CEO since June 2026 and brings over 20 years of experience in the medical device industry. His annual salary

Is Picard Medical a public company?

Yes. Picard Medical is publicly traded under the ticker PMI.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Picard Medical across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.